lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
The potential for Lexaria' biotech is quite remarkable
December 15, 2017 - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces a new topical skin cream research and development ("R&D") program; R&D into nicotine edibles; and updates existing R&D programs.
Topical Skin Formulations for Cannabinoids.
Lexaria has formulated topical cream products as an extension of its DehydraTECH(TM) technology, for the delivery of cannabinoids into and through the skin which may prove to have emollient benefits desired by the topical products sector. Lexaria's president, John Docherty M.Sc., has extensive experience as a biotech company executive and researcher for skin-based delivery of therapeutics.
Multiple Lexaria formulations are scheduled to be laboratory tested for human skin absorption and penetration characteristics during January through March 2018. Testing will be completed at a third-party lab utilizing human skin tissue and the latest in vitro evaluative techniques to measure cannabidiol penetration in the skin. Lexaria expects to optimize formulation and manufacturing processes to develop superior-performing product designs that will potentially be available to licensees during 2018.
Nicotine in Edible Formats.
Lexaria has accelerated its research focus on nicotine following its recently announced nicotine patent grant and has been researching edible forms of nicotine which could use the Company's DehydraTECHTM technology. Formulations have been prepared and are currently completing quality control testing, prior to in vivo absorption and tolerability testing in animals.
A third-party Philadelphia based lab has been contracted to perform the first nicotine edible tests expected in February. In vivo testing with rats will examine two main outcomes:
1) Gastrointestinal distress. Without an enabling technology, untreated nicotine causes gastrointestinal upset and distress making nicotine edibles impractical. The DehydraTECHTM process will be evaluated for its ability to lessen gastrointestinal distress thus potentially opening the door to the creation of a new line of consumer products.
2) Absorption time and efficiency in crossing the intestinal wall and reaching the bloodstream. Earlier testing of the DehyrdaTECHTM process using cannabidiol as an active ingredient, proved reduced absorption times and enhanced intestinal permeability. It is expected that similar outcomes using nicotine may be experienced.
University of British Columbia (UBC) TurboCBD(TM) Study.
As previously announced, the UBC study was initiated with UBC board evaluation and approvals. However, a recent change in UBC policy has resulted in all MITACS/UBC studies of this class to be temporarily halted. This change in policy affects numerous studies at UBC. Lexaria is currently reviewing methods of modifying the contemplated UBC study and/or alternatives to complete the planned study objectives at UBC or elsewhere if necessary and will report on next steps when they are known.
National Research Council.
The National Research Council and Lexaria have successfully developed model formulations using the DehydraTECH(TM) process and methodology. Following this completed first phase, the parties now plan to formulate and test DehydraTECH(TM) based cannabinoid formulations in early 2018 to determine the inherent processes that enable the palatability and absorption benefits DehydraTECH(TM) formulations have demonstrated. This second phase is expected to be performed with cannabinoids for the first time to provide additional guidance for further study.
Lexaria has conducted various cannabinoid formulation experiments, together with potential DehydraTECH(TM) licensee partners, on chocolates, candies, gummies, mouth-melts, chocolate bars, protein bars, beverages such as beer, spices, tea, coffee, supplements and more.
Beverage formulations have produced cannabinoid water-based products including de-alcoholized beer that mask unwanted cannabis flavor and are fast acting. Chocolate formulations were reported as being the fastest acting, most consistent, and best-tasting products in approximately 70% of cases in a recent consumer study. As the recreational markets for cannabis become legal in California and Canada, Lexaria expects increased demand for its superior-performing edible products. Its formulations further allow clients to retain organic food claims as the DehydraTECHTM process does not use any chemicals.
Lexaria will work with new and improved formulations for a variety of food products on a continuous basis throughout 2018 as it broadens its ever growing universe of products under development for potential licensees. This should shorten the technology licensing sales cycle and also assist companies as they collaborate with Lexaria to develop and sell the highest-performing products in their respective sales categories.
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Stock still holding in, for sure needed some consolidation, yesterdays news
2017-12-13 10:55 ET - News Release
Mr. Alex Blanchard reports
LEXARIA BIOSCIENCE RECEIVES U.S. PATENT AWARD FOR ITS DEHYDRATECH(TM) DELIVERY OF THC, NSAIDS, NICOTINE AND VITAMINS
The United States Patent and Trademark Office (USPTO) has granted patent No. 9,839,612 B2 to Lexaria Bioscience Corp. for the use of DehydraTech technology as a delivery platform for a wide variety of active pharmaceutical ingredients (APIs) including all cannabinoids including tetrahydrocannabinol; fat soluble vitamins; non-steroidal anti-inflammatory pain medications (NSAIDs); and nicotine.
This granted patent completes the patent allowance process that was announced on Oct. 31, 2017, and this patent grant is now final. The title of the granted patent is "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof." This issued patent protects Lexaria's intellectual property (IP) for the DehydraTech delivery of all the active substances noted via nearly any kind of processed food or beverage as well as capsules and pills.
In one aspect a method of treating a condition is provided wherein a cannabinoid is used to treat conditions selected from the group consisting of cardiac diseases such as heart disease, ischemic infarcts and cardiometabolic disorders; neurological diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia and human immunodeficiency virus (HIV) dementia; obesity; metabolic disorders such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes and appetite disorders; cancer chemotherapy, benign prostatic hypertrophy; irritable bowel syndrome, biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine or cocaine addiction.
Lexaria also continues to advance all of its additional patent applications in various countries as it levers patent success in the United States. For example, some of the company's patent applications have recently entered the active patent investigation phase in China, the European Union and in Canada.
"Lexaria has now locked up the IP for its next-generation drug delivery system," said chief executive officer Chris Bunka. "This groundbreaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market."
Lexaria's patented DehydraTech technology is focused on improved delivery methodologies of many commonly used API substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
Lexaria is presently investigating and will continue to pursue additional technologies that could deliver value to its growing portfolio of patented technologies.